[A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients].
BACKGROUND
Leukotrienes participate in certain biological activities such as contraction of human airway muscle, increased vascular permeability, chemotaxis and allergen-induced early and late responses.


OBJECTIVE
To evaluate the leukotriene antagonist montelukast in patients with atopic dermatitis unresponsive to traditional treatment.


METHODS
Eighteen children with atopic dermatitis were treated with 5 mg of chewable montelukast every 24 hs during a period of 24 weeks. Patient's history was utilized as a control for each individual. On each visit, every child was assessed by a single observer and objectively scored for disease extent and severity. In addition every parent filled a similar evaluation.


RESULTS
There was statistical improvement (p < 0.01) when values before and after treatment were analyzed, although no improvement was reported in five. No adverse reactions were reported.


CONCLUSIONS
Findings suggest that leukotriene antagonists can be used as an adjunct treatment on patients with atopic dermatitis that are refractory to traditional management.
Concha del Río
Luz Elena
LE
Facultad Medicina, Universidad Autónoma de Querétaro.
Arroyave
Carlos M
CM
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D013440:Sulfides; D016896:Treatment Outcome
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast